Metabolik sendromda preptin düzeyinin kardiyovasküler risk faktörleriyle ilişkisi
Yükleniyor...
Dosyalar
Tarih
2020
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Tekirdağ Namık Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Metabolik sendrom başlangıçta insülin direnci varlığı ile meydana gelen bunu takiben obezite, diyabet, lipid profili bozukluğu olan dislipidemi ve çeşitli kardiyovasküler rahatsızlıkların metabolik bozukluklarını bir çatı altında birleştiren bir endokrin bozukluktur. Dünya üzerinde ciddi bir problem olarak karşımıza çıkan metabolik sendromda, görülme sıklığının nedeni deneklerin bireysel özellikleri ve hayat tarzları ile araştırmanın yapıldığı zaman aralığı ileri sürülmüştür. Metabolik sendromlu kişilerde görülen subklinik kardiyovasküler hastalıkların varlığının da kardiyovasküler hastalık riskinin artmasında etkili olduğu ileri sürülmüştür. Dünyada hızlıca yayılan diyabet ve metabolik sendrom, araştırmacıları bu hastalıkların tanı, tedavi ve patogenezinde görev alan ayıraçlar hususunda araştırmaya yönlendirmiştir. Bu araştırmaların sonucunda da kardiyovasküler hastalıkların önüne geçilebileceği umut edilmektedir. Çalışmamızdaki amacımız yakın zamanda keşfedilen yeni bir peptid olan preptinin metabolik sendromla olan ilişkisini incelemek ve buna bağlı olarak kardiyovasküler risk faktörleriyle ilişkisini değerlendirebilmektir. Çalışmaya 58 metabolik sendrom hastası deney grubu ve 30 sağlıklı birey kontrol grubu olarak alındı. Metabolik sendromlu hastalarda preptin, yaş, bel çevresi, kalça çevresi, sistolik kan basıncı, diastolik kan basıncı, glukoz, insülin, LDL, HDL, total kolesterol, TG, HOMA, HbA1c, VKİ, QUICKI, SCORE risk değerlendirmesi kontrol grubuna göre anlamlı olarak yüksek bulundu (sırasıyla p=0,000, p=0,000, p=0,000, p=0,000, p=0,000, p=0,000, p=0,005, p=0,000, p=0,000 p=0,008, p=0,000, p=0,033, p=0,000, p=0,043, p=0,000, p=0,000, p=0,000). Metabolik sendrom hasta grubuna uygulanan korelasyon analizinde Preptin düzeyi ile bel çevresi, sistolik kan basıncı, HOMA ve VKİ arasında pozitif korelasyon tespit edildi (sırasıyla r=0,324 p<0,005, r=0,293 p<0,05, r=0,332 p<0,05, r=0,308 p<0,05). Metabolik sendrom hasta grubu VKİ ve SCORE risk yönünden 4 farklı alt grup altında preptin seviyesi ile ilişkisi değerlendirildi. VKİ ve SCORE risk arttıkça preptin seviyelerinde de artış olduğu gözlemlendi. Sonuç olarak metabolik sendromlu hastalarda yükselen düzeyleri nedeniyle, preptinin kardiyovasküler risk faktörlerini belirlemede yardımcı olabilecek olan bir peptit olabileceği öngörülmüştür.
Metabolic syndrome is an endocrinopathy in which systemic disorders such as abdominal obesity, glucose intolerance or diabetes mellitus, hypertension, coronary artery disease (CAD) and dyslipidemia first appear with insulin resistance. In the metabolic syndrome, which is a serious problem in the world, it has been suggested that the frequency of occurrence and the individual characteristics and lifestyles of the subjects and the time interval during which the research was conducted. It has been suggested that the presence of subclinical cardiovascular diseases in people with metabolic syndrome is also effective in increasing the risk of cardiovascular disease. The rapidly spreading diabetes and metabolic syndrome in the world has directed researchers to investigate the molecules involved in the diagnosis, treatment and pathogenesis of these diseases. As a result of these studies, it is hopeful that cardiovascular diseases can be prevented. Our aim in our study is to examine the relationship of preptin, a recently discovered peptide, with metabolic syndrome and to evaluate its relation with cardiovascular risk factors. 58 metabolic syndrome patients were included in the study as experimental group and 30 healthy individuals as control group. Risk assessment of preptin, age, waist circumference, hip circumference, systolic blood pressure, diastolic blood pressure, glucose, insulin, LDL, HDL, total cholesterol, triglyceride, HOMA, HbA1c, BMI, QUICKI, SCORE was significantly higher in patients with metabolic syndrome compared to the control group. (respectively p=0,000, p=0,000, p=0,000, p=0,000, p=0,000, p=0,000, p=0,005, p=0,000, p=0,000 p=0,008, p=0,000, p=0,033, p=0,000, p=0,043, p=0,000, p=0,000,p=0,000). In the correlation analysis applied to the metabolic syndrome patient group, a positive correlation was found between Preptin level and waist circumference, systolic blood pressure, HOMA and BMI. (respectively r=0,324 p<0,005, r=0,293 p<0,05, r=0,332 p<0,05, r=0,308 p<0,05). Metabolic syndrome patient group were evaluated for relationship between BMI and SCORE with preptin levels under 4 different subgroups. As BMI and SCORE risk increased, preptin levels also increased. As BMI and SCORE risk increased, preptin levels also increased. Consecuently, it has been predicted that due to its elevated levels in patients with metabolic syndrome, preptin may be a peptide that may assist in determining cardiovascular risk factors.
Metabolic syndrome is an endocrinopathy in which systemic disorders such as abdominal obesity, glucose intolerance or diabetes mellitus, hypertension, coronary artery disease (CAD) and dyslipidemia first appear with insulin resistance. In the metabolic syndrome, which is a serious problem in the world, it has been suggested that the frequency of occurrence and the individual characteristics and lifestyles of the subjects and the time interval during which the research was conducted. It has been suggested that the presence of subclinical cardiovascular diseases in people with metabolic syndrome is also effective in increasing the risk of cardiovascular disease. The rapidly spreading diabetes and metabolic syndrome in the world has directed researchers to investigate the molecules involved in the diagnosis, treatment and pathogenesis of these diseases. As a result of these studies, it is hopeful that cardiovascular diseases can be prevented. Our aim in our study is to examine the relationship of preptin, a recently discovered peptide, with metabolic syndrome and to evaluate its relation with cardiovascular risk factors. 58 metabolic syndrome patients were included in the study as experimental group and 30 healthy individuals as control group. Risk assessment of preptin, age, waist circumference, hip circumference, systolic blood pressure, diastolic blood pressure, glucose, insulin, LDL, HDL, total cholesterol, triglyceride, HOMA, HbA1c, BMI, QUICKI, SCORE was significantly higher in patients with metabolic syndrome compared to the control group. (respectively p=0,000, p=0,000, p=0,000, p=0,000, p=0,000, p=0,000, p=0,005, p=0,000, p=0,000 p=0,008, p=0,000, p=0,033, p=0,000, p=0,043, p=0,000, p=0,000,p=0,000). In the correlation analysis applied to the metabolic syndrome patient group, a positive correlation was found between Preptin level and waist circumference, systolic blood pressure, HOMA and BMI. (respectively r=0,324 p<0,005, r=0,293 p<0,05, r=0,332 p<0,05, r=0,308 p<0,05). Metabolic syndrome patient group were evaluated for relationship between BMI and SCORE with preptin levels under 4 different subgroups. As BMI and SCORE risk increased, preptin levels also increased. As BMI and SCORE risk increased, preptin levels also increased. Consecuently, it has been predicted that due to its elevated levels in patients with metabolic syndrome, preptin may be a peptide that may assist in determining cardiovascular risk factors.
Açıklama
Anahtar Kelimeler
Biyokimya, Biochemistry, Hiperlipidemiler, Hyperlipidemias, Kardiyovasküler hastalıklar, Cardiovascular diseases, Kardiyovasküler sistem, Cardiovascular system, Metabolik sendrom, Metabolic syndrome, Preptin, Preptin, Risk faktörleri, Risk factors, İnsülin direnci, Insulin resistance, Metabolik Sendrom, Preptin, Kardiyovasküler risk, İnsülin direnci, Hiperlipidemi, HOMA., Metabolic Syndrome, Preptin, Cardiovasculer risk, Insulin rezistance, Hyperlipidemia, HOMA.
